Skip to main content

Drug Safety

      To remind us. Glory be! GLORIA a #RCT in elderly active #RA: MTX+10 mg daily #prednisolone which was better than MTX alo

      Janet Pope

      1 year 10 months ago
      To remind us. Glory be! GLORIA a #RCT in elderly active #RA: MTX+10 mg daily #prednisolone which was better than MTX alone. But more infections and no comparison of inexpensive Rx such as adding #HCQ. Still debated as to benefit vs risk of this strategy @RheumNow #ACR23 @ACRheum https://t.co/slOmESbIOW
      The RheumNow faculty reporters have been scouring the meeting for what they believe to be the best presentations from the first day at ACR 2023 in San Diego.  From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from Sunday Nov. 12th. You can spot these on Twitter by looking for the (#ACRbest) hashtag.
      Super interesting study re: impact of ORAL SURVEILLANCE on prescribing

      Post safety report, JAK pts shifted younger w/lo

      Mike Putman EBRheum

      1 year 10 months ago
      Super interesting study re: impact of ORAL SURVEILLANCE on prescribing Post safety report, JAK pts shifted younger w/lower comorbidities (esp CVD) I know many have mixed feelings, but I believe in the risk & support this type of shift @RheumNow Abstr0435 #ACR23 https://t.co/EBg9VOIbj1
      No more underpowered long-term safety studies

      We need a "SELECT-SURVEILLANCE" study to replicate ORAL-SURVEILLANCE &amp

      Mike Putman EBRheum

      1 year 10 months ago
      No more underpowered long-term safety studies We need a "SELECT-SURVEILLANCE" study to replicate ORAL-SURVEILLANCE & tell us if UPA has the same MACE/cancer risk as TOFA Minus that, I plan to go 100% TOFA when it becomes generic in 2026 @RheumNow #ACR23 Abstr1326 https://t.co/LyQ1Q8qReO
      Real-life data about the PEXIVAS reduced-dose glucocorticoid regimen in #granulomatosis with polyangiitis and microscopi

      Alessia Alunno

      1 year 10 months ago
      Real-life data about the PEXIVAS reduced-dose glucocorticoid regimen in #granulomatosis with polyangiitis and microscopic #polyangiitis (Abstract 0725 https://t.co/7x34Hr0OMP) @TerrierBen #ACR23 #ACRambassador https://t.co/D8UfZvXQCl
      ABS0524:

      ⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) fl

      Meral K. El Ramahi, MD MeralElRamahiMD

      1 year 10 months ago
      ABS0524: ⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) flares among high risk pts w/ axSpA ➡️active dz, HLAB27+, 2 or more AAU flares ⭐️CZP reduced AAU flare rate by 87% #ACR23 @RheumNow #ACRBest https://t.co/rW0N18agMO
      Are we tapering steroids too rapidly? Real world experience: steroid tapering in severe #AAV based on #PEXIVAS protocol

      TheDaoIndex KDAO2011

      1 year 10 months ago
      Are we tapering steroids too rapidly? Real world experience: steroid tapering in severe #AAV based on #PEXIVAS protocol noted higher rates of dz progression, relapse, ESRD, death. Risk greatest when creatinine > 300umol/L and w/RTX induction #Plenary1 #ACR23 Abst#0725 #ACrBest https://t.co/Rtv7vkzUUD
      Ph2a Nipocalumab: FcRn blocker
      IV15mg/kg TNF IR RA 32 pts
      Delta DASCRP -1 vs -0.5 PBO
      ACR50 20% vs 0 PBO
      DAS Remission 4

      Aurelie Najm

      1 year 10 months ago
      Ph2a Nipocalumab: FcRn blocker IV15mg/kg TNF IR RA 32 pts Delta DASCRP -1 vs -0.5 PBO ACR50 20% vs 0 PBO DAS Remission 40% vs 16% Only in ACPA+ pts SAEs 1 infusion related reaction Not extremely convincing alone Currently studied in combination w/ TNFi @RheumNow #ACR23 ABST0839 https://t.co/6wTu2ellhN
      Lots of our patients taking CBD products, and they won’t always tell us…

      but if you don’t ask, you’ll miss the

      David Liew drdavidliew

      1 year 10 months ago
      Lots of our patients taking CBD products, and they won’t always tell us… but if you don’t ask, you’ll miss the drug-drug interaction that affects the meds we rely on. #ACR23 @US_FDA session @RheumNow https://t.co/Q9UMJiTDkq
      Ab#498 Does DMARD for PsO and PsA decrease MACE?
      #ACR23 @RheumNow
      Retrospective database Israeli study.
      PsO, PsA on MTX

      Eric Dein

      1 year 10 months ago
      Ab#498 Does DMARD for PsO and PsA decrease MACE? #ACR23 @RheumNow Retrospective database Israeli study. PsO, PsA on MTX or bDMARD: lower MACE compared to health matched controled (HR 0.45-0.68, p<0.001) Pts on topical Rx had marginally Increased MACE (HR 1.14, p <0.001) https://t.co/0uRgjzYbFp
      #Benefits of #hudroxychloroquine - reduced lipids, clots, CV events, infection AND now improved #fatty #liver #NAFLD….

      Janet Pope

      1 year 10 months ago
      #Benefits of #hudroxychloroquine - reduced lipids, clots, CV events, infection AND now improved #fatty #liver #NAFLD….@RheumNow #ACR23 @ACRheum https://t.co/Y43JETY6F3
      Important plenary re:reduced vs standard GC for AAV... IRL

      PEXIVAS & recent guidelines supported low dose taper

      Re

      Mike Putman EBRheum

      1 year 10 months ago
      Important plenary re:reduced vs standard GC for AAV... IRL PEXIVAS & recent guidelines supported low dose taper Real world data w/severe dx? Increased risk of death & ESKD for REDUCED pts Need full data but yikes... @RheumNow #ACR23 #ACRBest https://t.co/3S23O9d1ok
      Interesting study on PEXIVAS reduced steroid use from today's plenary session!
      Reduced steroid dose in GPA/MPA pts assoc

      Robert B Chao, MD

      1 year 10 months ago
      Interesting study on PEXIVAS reduced steroid use from today's plenary session! Reduced steroid dose in GPA/MPA pts associated w/ INCREASED risk of death, ESKD, progression of dz Even greater risk in pts with higher Cr lvls or RTX induction use @RheumNow #ACR23 Abs#0725 #ACRbest https://t.co/frsOrANKhf
      ×